Stocks of the Hour: Actinogen Medical, Kalina Power, Iltani Resources
Actinogen Medical (ASX:ACW) has announced positive results from its XanaCIDD phase 2a depression trial. Xanamem, the company’s drug candidate, demonstrated consistent benefits in reducing depression symptoms across multiple endpoints, suggesting its potential as a novel treatment for Major Depressive Disorder. Shares are trading 104.17 per cent higher 4.9 cents. Kalina Power (ASX:KPO) signed a non-binding […]
Stocks of the Hour: Actinogen Medical, Kalina Power, Iltani Resources Read More »